Pseudomonas Aeruginosa Infection Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The Pseudomonas aeruginosa infection treatment market is expected to register a CAGR of 4.7% during the forecast period.

The market expanded during COVID-19 because some of the patients who received COVID-19 therapy in hospitals and other healthcare institutions had pseudomonas aeruginosa infections as a result of the use of ventilators and other medical devices. According to the study published in Cell Reports in August 2021, it was found that Pseudomonas aeruginosa, a common coinfecting infection in COVID-19 patients, causes illness aggravation. Pseudomonas aeruginosa abundance increases with SARS-CoV-2 viral RNA load. Individuals infected with P. aeruginosa and suffering from COVID-19 pneumonia were given 'oral ciprofloxacin' drug formulations. Thus, the studies demonstrated that COVID-19 had a favourable impact on the growth of the studied market. However, the COVID-19 infection cases have been subsidized currently, studied market is expected to project stable growth over the forecast period due to the rising burden of pseudomonas aeruginosa infection.

The major factors such as the increasing incidence of infections associated with it such as pneumonia, cystic fibrosis, and urinary tract infections, the increasing development of products, increasing antibacterial resistance, and growing R&D activities are driving the growth of the Pseudomonas aeruginosa infection market.

The prevalence of hospital-acquired infections has increased in recent years. According to an article published in the National Library of Medicine in August 2022, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 and 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. As a result of the increased burden of P. aeruginosa infection, the demand for its treatment is predicted to rise over the projection period, thereby boosting the growth of the studied market.

Furthermore, growing research and development activities on pseudomonas aeruginosa infection are expected to support market expansion over the forecast period. For instance, according to ClinicalTrials.gov updated in October 2022, a study titled 'A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa' is under phase II trials and expected to be completed by 2024. Thus, such a study is expected to bring an advanced product for treating pseudomonas aeruginosa infection, thereby boosting the market's growth.

Various organic and inorganic strategies by the market players are likely to support the growth of the market. For instance, in April 2021, UK-based Phico Therapeutics secured an initial USD 5.3 million grant from CARB-X for developing intravenous-engineered bacteriophage drugs to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Thus, all the aforementioned factors, such as the growing prevalence of pseudomonas aeruginosa infection and rising drug development and discovery activities, are expected to propel the growth of the market over the forecast period. However, drug resistance ability of pseudomonas aeruginosa may restraint the market growth over the forecast period.

Key Market Trends

Combination Therapy is Expected to Hold a Significant Share Over the Forecast Period.

Combination therapy for the treatment of P. aeruginosa is administered due to different considerations - first, to cover the known or suspected pathogen while results of identification and susceptibility testing are pending; second, to avoid the emergence of resistance during treatment; and third, due to possible synergistic activity resulting in better clinical outcome.

According to an article published in Antibiotics in November 2021, antimicrobial susceptibility testing showed that P. aeruginosa strains were highly resistant to ceftazidime (88.9%) and cefepime (82.2%), which were the most prevalent among wound infections. Imipenem and amikacin were the most effective drugs with the least resistance percentage (28.9%). The research concluded that the drug combination viewed a statistically significant reduction in bacterial counts when receiving definite combination therapy, compared to monotherapy, and combination therapy showed good results.

Additionally, the rise in demand for combination therapy for the treatment of pseudomonas aeruginosa infection is attributed to the rapid onset of action, high bioavailability rate, cost saving, and high efficiency. Thus, due to the benefits of combination therapy over monotherapy, this segment is expected to grow during the forecast period.

North America is Expected to Hold a Significant Share Over the Forecast Period

North America is expected to hold a significant share owing to the increase in hospital stays due to chronic diseases and surgeries, the rising number of hospital admissions, the increasing burden of hospital-acquired infection coupled with the innovative technologies implemented in devices that control infection, and others.

An increase in hospital-acquired infections is expected to propel the growth of the studied market in the North America region. According to Statistics Canada in a report published in January 2022, each year, many Canadians acquire an infection during their hospital stay that increases morbidity and mortality, and that bears a financial cost to the healthcare system. Every year, it is estimated that 220,000 Canadian patients develop an HAI. Thus, a growing burden of hospital-acquired infection in Canada is expected to support the market expansion over the forecast period.

Additionally, the rise in chronic diseases such as cardiovascular diseases, cancer, and others requires extended hospital stays and surgeries. For instance, according to 2022 data from the American Health Association, there were approximately 33,356,853 hospital admissions in 2022. Many of these admissions were due to chronic diseases and critical procedures like heart bypass surgery. Thus, the increasing number of hospital admissions is expected to create a need for infection control products and thereby boost the market in the region.

Additionally, various strategies adopted by the market players, such as product launches, mergers, and acquisitions, are expected to propel the growth of the market. For instance, in May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., launched its generic Erythromycin tablets in availble in 250 mg and 500 mg strengths, it is a therapeutic equivalent for Arbor Pharmaceuticals' reference listed drug (RLD) Erythromycin Tablets. Teva generic Erythromycin pills are used to treat a wide range of bacterial illnesses, including pneumonia.

Thus, the growing burden of hospital-acquired infection coupled with hospital admission is expected to boost the market growth in the North America region over the forecast period.

Competitive Landscape

The pseudomonas aeruginosa infection treatment market is fragmented and consists of several players. The majority of the Pseudomonas aeruginosa infection treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution systems have established their positions in the market. Some of the market players are Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc., Merck & Co Inc., AbbVie Inc. (Allergan)

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.